Opendata, web and dolomites

PROTOCOL

New processing technology for colistmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROTOCOL project word cloud

Explore the words cloud of the PROTOCOL project. It provides you a very rough idea of what is the project "PROTOCOL" about.

viability    ingredients    active    supply    economic    instrument    plan    thorough    feasibility    business    maximize    limitations    energetic    phd    commercialization    formulation    freeze    financial    scaling    market    form    coupled    veterinary    commercialized    evaporation    lc    markets    alternative    2012    pharmaceutical    hplc    sodium    effect    chemical    manufacturing    industrial    antibiotic    resistant    pyrogenic    agent    validation    minimize    perform    sterile    chances    pathogens    returns    medicine    opportunity    infections    founded    custom    life    sme    outstanding    innovation    price    commercial    relies    advantages    aqueous    gram    negative    post    practical    nosocomial    actual    ultrafiltration    staff    cidqo    final    cms    quality    expertise    exploited    ms    multidrug    bactericidal    antimicrobial    drying    risks    combination    hereinafter    delivered    finish    verify    solutions    threatening    good    colistimethate    treatment   

Project "PROTOCOL" data sheet

The following table provides information about the project.

Coordinator
CIDQO 2012 SL 

Organization address
address: POLIGONO INDUSTRIAL CAN VERDALET CARRER D NAU 91
city: TORDERA
postcode: 8490
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.cidqo.com/Noticias/News/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CIDQO 2012 SL ES (TORDERA) coordinator 50˙000.00

Map

 Project objective

Colistimethate Sodium (CMS hereinafter) is a rapidly bactericidal antimicrobial agent with a significant post-antibiotic effect against multidrug resistant Gram-negative pathogens. CMS represents a reliable alternative for the treatment of life-threatening nosocomial infections but today the market supply of CMS relies on industrial processes based on freeze drying of CMS aqueous solutions. This represents outstanding energetic costs that directly affect the final price of CMS. CIDQO is an SME founded in 2012 and its PhD staff has a wide expertise and know-how on the development and scaling-up of chemical processes, as well as on custom manufacturing of active pharmaceutical ingredients. CIDQO aims to undertake an innovation project to solve the current limitations of CMS supply, through the industrial validation of a new processing technology based on the combination of ultrafiltration and evaporation coupled to HPLC/LC-MS. The key market opportunity of the new processing technology relies on its ability to deliver a non-pyrogenic and sterile CMS formulation to be commercialized on the Pharmaceutical and Veterinary medicine markets, which will represent several advantages in terms of price and quality compared with the current commercial form. The overall plan to reach the market needs to be defined in the short term since the innovation process is next to finish. Phase 1 of SME Instrument represents a good opportunity to get the financial support required to perform a thorough market study not only to minimize risks but also to set up a business plan for commercialization. The main objective is to perform a thorough feasibility study to verify the practical and economic viability in Pharmaceutical and Veterinary markets of the CMS form to be delivered by the new processing technology. The actual market chances that can be exploited to maximize the economic returns will be analyzed and a detailed business plan will be developed.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROTOCOL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROTOCOL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.

Read More  

NANOHIGH (2015)

High volume production facility for high accuracy nanocapsules

Read More  

InLineNano (2015)

In-Line Areal Surface Measurement for Micro and Nano Production

Read More